** Brokerage Citi initiates coverage on 89bio ETNB.O with "buy" rating
** Brokerage sets PT at $25, representing a near triple upside to the stock's last close
** Citi remains optimistic about co's experimental drug, pegozafermin, for patients with a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH)
** "If 89bio can replicate its early results of pegozafermin in larger trials and show a synergistic effect when used in combination of GLP-1s, pegozafermin could become a significant player in the MASH space", says Citi
** Eight of 9 brokerages rate the stock "buy" or higher, 1 "hold"; their median PT is $29.67, according to data compiled by LSEG
** Up to last close, ETNB has fallen 35.1% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。